within Pharmacolibrary.Drugs.ATC.D;

model D06AX11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.0005366666666666666,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011699999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D06AX11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rifaximin is a non-systemic, semisynthetic antibiotic derived from rifamycin. It is primarily used to treat travelers' diarrhea caused by noninvasive strains of Escherichia coli and to reduce the risk of hepatic encephalopathy in patients with liver disease. It is also used in the management of irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is approved for use in several countries, including the US and Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following oral administration; non-compartmental analysis.</p><h4>References</h4><ol><li><p>Trapnell, CB, et al., &amp; Bettenhausen, DK (2007). Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. <i>The Annals of pharmacotherapy</i> 41(2) 222–228. DOI:<a href=\"https://doi.org/10.1345/aph.1H395\">10.1345/aph.1H395</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17284510/\">https://pubmed.ncbi.nlm.nih.gov/17284510</a></p></li><li><p>Pentikis, HS, et al., &amp; Bettenhausen, DK (2007). The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. <i>Pharmacotherapy</i> 27(10) 1361–1369. DOI:<a href=\"https://doi.org/10.1592/phco.27.10.1361\">10.1592/phco.27.10.1361</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17896891/\">https://pubmed.ncbi.nlm.nih.gov/17896891</a></p></li><li><p>Taylor, DN, et al., &amp; Bourgeois, AL (2008). Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. <i>Antimicrobial agents and chemotherapy</i> 52(3) 1179–1181. DOI:<a href=\"https://doi.org/10.1128/AAC.01108-07\">10.1128/AAC.01108-07</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18086855/\">https://pubmed.ncbi.nlm.nih.gov/18086855</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D06AX11;
